Recent advances in the management and understanding of macular degeneration [version 1; referees: 2 approved]

F1000Research

Michael Singer¹  Sepehr Bahadorani² 

[1] Medical Center Ophthalmology Associates, San Antonio, TX, USA;University of Texas Health Science Center at San Antonio, San Antonio, TX, USA;

关键词: Genetics of the Immune System;    Glaucoma;    Immunopharmacology & Hematologic Pharmacology;    Innate Immunity;    Neurobiology of Disease & Regeneration;    Neuro-Ophthalmology & Neuro-Otology;    Neuropharmacology & Psychopharmacology;    Retinal, Vitreous & Macular Disorders;    Stem Cells & Regeneration;   

DOI  :  10.12688/f1000research.10998.1

来源: DOAJ

【 摘 要 】

Current management of age-related macular degeneration (AMD) is directed at intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors for the treatment of wet AMD and supplementation with oral antioxidants for the treatment of dry AMD. In this article, we will review recent clinical trials for the treatment of dry and wet AMD.

【 授权许可】

Unknown